Go to deals
Healthcare

Protalix BioTherapeutics, Inc. has completed a private stock placement

Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.

Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Ruben  Eblagon

Ruben Eblagon

Principal

Tel Aviv, Israel
Oaklins Rosario
 Boaz  Levi

Boaz Levi

Partner

Tel Aviv, Israel
Oaklins Rosario
 Olga  Geyber

Olga Geyber

Support

Tel Aviv, Israel
Oaklins Rosario

Related deals

CAPZA and RAISE Impact have invested in Oui Care to accelerate its internal and external growth strategies
Consumer & Retail

CAPZA and RAISE Impact have invested in Oui Care to accelerate its internal and external growth strategies

The shareholders and management of Oui Care have raised funds and restructured its debt for up to US$78.5 million (US$42.2 million for external growth and US$36.3 million in refinancing). This investment will support Oui Care and its management in this new stage of development.

Learn more
Kardan Real Estate has issued bonds
Real Estate

Kardan Real Estate has issued bonds

Kardan Real Estate Ltd. has completed a fundraising to develop the business.

Learn more
Ace Pharmaceuticals has been acquired by Gilde Buy Out Partners, Gilde Healthcare and Quadrum Capital
Private Equity | Healthcare

Ace Pharmaceuticals has been acquired by Gilde Buy Out Partners, Gilde Healthcare and Quadrum Capital

Ace Pharmaceuticals BV has been acquired by Gilde Buy Out Partners, Gilde Healthcare, Quadrum Capital and the management team.

Learn more